BioSenic signs a new subscription agreement for a maximum of EUR 2.1M in convertible bonds
PRESS RELEASE – PRIVILEGED INFORMATION
Excerpt from:
BioSenic signs a new subscription agreement for a maximum of EUR 2.1M in convertible bonds
Category Archives: Global News Feed
Mustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
WORCESTER, Mass., June 21, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell therapies into potential cures for difficult-to-treat cancers, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules, for the issuance and sale of an aggregate of 6,130,000 of its shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $0.41 per share (or common stock equivalent in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, Mustang also issued unregistered warrants to purchase up to an aggregate of 6,130,000 shares of its common stock. The unregistered warrants have an exercise price of $0.41 per share, are exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the warrants and will expire five years from the date of stockholder approval.
See the original post here:
Mustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Results of the votes of the Combined Shareholders’ General Meeting of June 20, 2024
Daix (France), Long Island City (New York, United States), on June 21, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the results of the votes of its Combined Shareholders’ Meeting.
View post:
Results of the votes of the Combined Shareholders’ General Meeting of June 20, 2024
HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda
— Approval for previously treated metastatic colorectal cancer based on results from positive, global, Phase III FRESCO-2 Trial —
More here:
HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda
Inozyme Pharma Announces Presentation and Sponsored Symposium at the 11th International Conference on Children’s Bone Health (ICCBH)
Results from a radiographic study describing skeletal features of pediatric patients with ENPP1 Deficiency will be presented Results from a radiographic study describing skeletal features of pediatric patients with ENPP1 Deficiency will be presented
The rest is here:
Inozyme Pharma Announces Presentation and Sponsored Symposium at the 11th International Conference on Children’s Bone Health (ICCBH)
On Path to First-in-Human Study, NurExone Engages Prominent Expert in Biological Drug Development
TORONTO and HAIFA, Israel, June 21, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, welcomes Dr. Yona Geffen, as a consultant, to support the Company’s preclinical and clinical activities. Dr. Geffen, who currently serves as Vice President of Research and Development at Gamida Cell Ltd. (“Gamida Cell”), brings over two decades of extensive experience in leading clinical and drug development in the biotechnology and pharmaceutical industries. Under her leadership, Gamida Cell obtained United States Food and Drug Administration approval for Omisirge®, a groundbreaking stem cell therapy.
Read the rest here:
On Path to First-in-Human Study, NurExone Engages Prominent Expert in Biological Drug Development
argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy
VYVGART® Hytrulo is first and only neonatal Fc receptor (FcRn) blocker approved to treat chronic inflammatory demyelinating polyneuropathy (CIDP)
See more here:
argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy
Cronos Group Inc. Announces Results of 2024 Annual Meeting of Shareholders
TORONTO, June 21, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) announces that at its Annual Meeting of Shareholders held yesterday, June 20, 2024 (the “Meeting”), shareholders holding a total of 274,097,252 common shares of the Company voted in person or by proxy, representing 71.75% of the total number of common shares of the Company outstanding.
See more here:
Cronos Group Inc. Announces Results of 2024 Annual Meeting of Shareholders
Altimmune Presents Data on the Effect of Pemvidutide on Cardioinflammatory Lipids during Oral Presentation at American Diabetes Association’s 84th…
Pemvidutide elicited significant weight loss and decreases in pro-inflammatory serum lipids associated with atherogenesis and cardiovascular disease risk Pemvidutide elicited significant weight loss and decreases in pro-inflammatory serum lipids associated with atherogenesis and cardiovascular disease risk